Compare SXT & PTCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SXT | PTCT |
|---|---|---|
| Founded | 1882 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5B | 5.5B |
| IPO Year | 1994 | 2006 |
| Metric | SXT | PTCT |
|---|---|---|
| Price | $134.02 | $59.27 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 15 |
| Target Price | ★ $144.40 | $100.33 |
| AVG Volume (30 Days) | 303.4K | ★ 1.2M |
| Earning Date | 10-30-2026 | 10-29-2026 |
| Dividend Yield | ★ 1.23% | N/A |
| EPS Growth | 7.48 | ★ 264.48 |
| EPS | ★ 2.24 | 0.90 |
| Revenue | ★ $1,396,499,000.00 | $264,734,000.00 |
| Revenue This Year | $11.85 | N/A |
| Revenue Next Year | $13.72 | $9.47 |
| P/E Ratio | ★ $59.44 | $67.73 |
| Revenue Growth | N/A | ★ 36.19 |
| 52 Week Low | $82.60 | $58.80 |
| 52 Week High | $138.82 | $90.87 |
| Indicator | SXT | PTCT |
|---|---|---|
| Relative Strength Index (RSI) | 59.57 | 34.70 |
| Support Level | $131.37 | N/A |
| Resistance Level | $137.17 | $68.93 |
| Average True Range (ATR) | 3.27 | 1.93 |
| MACD | 0.42 | -0.15 |
| Stochastic Oscillator | 68.91 | 13.82 |
Sensient Technologies Corp manufactures and markets natural and synthetic colors, flavors, and other specialty ingredients. Sensient's offerings are predominantly applied to consumer-facing products, including food and beverage, cosmetics and pharmaceuticals, nutraceuticals, and personal care industries. Its principal products are flavors, flavor enhancers, ingredients, extracts, and bionutrients, essential oils, dehydrated vegetables and other food ingredients, natural and synthetic food and beverage colors, and others. The company's reportable segments are: Flavors & Extracts, which derive key revenue, Color, Asia Pacific, and Corporate and Other. Geographically, the company generates maximum revenue from North America, followed by Europe, Asia-Pacific, and other regions.
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company views its operations and manages its business in one operating segment: life science, which is focused on the discovery, development and commercialization of the company's clinically differentiated medicines that provide benefits to patients with rare disorders.